相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts
Adam Ciesiolka et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Song Zhang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Candidate Alzheimer's Disease Biomarker miR-483-5p Lowers TAU Phosphorylation by Direct ERK1/2 Repression
Siranjeevi Nagaraj et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer's disease
Bin He et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer's Disease
Zhongli Shi et al.
AGING CELL (2020)
Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
Lei Sheng et al.
NUCLEIC ACIDS RESEARCH (2020)
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Sarah Bajan et al.
CELLS (2020)
Amyloid β-protein and beyond: the path forward in Alzheimer's disease
Dominic M. Walsh et al.
CURRENT OPINION IN NEUROBIOLOGY (2020)
An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
Shane G. Poplawski et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease
Ana Teresa Barros-Viegas et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
The biochemical basis for the cooperative action of microRNAs
Daniel Briskin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease
Yu-Wen Cheng et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
C. Frank Bennett et al.
Annual Review of Neuroscience (2019)
Consequences of Metabolic Disruption in Alzheimer's Disease Pathology
J. C. Ryu et al.
NEUROTHERAPEUTICS (2019)
BACE1 Inhibition Using 2'-OMePS Steric Blocking Antisense Oligonucleotides
Madhuri Chakravarthy et al.
GENES (2019)
Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions
Maria Munoz-San Martin et al.
JOURNAL OF NEUROINFLAMMATION (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Emerging roles of microRNAs in cancer
Ivan Vannini et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2018)
Targeting Amyloid-β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β Production
Jennifer L. Chang et al.
MOLECULAR THERAPY (2018)
Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer's disease models
Sayuri Higaki et al.
PLOS ONE (2018)
Functional miRNAs in breast cancer drug resistance
Weizi Hu et al.
ONCOTARGETS AND THERAPY (2018)
Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier
Bruno M. D. C. Godinho et al.
MOLECULAR THERAPY (2018)
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease
Sarah K. Baker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Recep Bayraktar et al.
CANCER AND METASTASIS REVIEWS (2018)
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease
Dan Liu et al.
MOLECULAR THERAPY (2017)
A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain
Jun Wang et al.
NATURE REVIEWS NEUROLOGY (2017)
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Tien-Phat V. Huynh et al.
NEURON (2017)
Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases
Kathie M. Bishop
NEUROPHARMACOLOGY (2017)
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Sarah L. DeVos et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Anti-dementia Effects of Donepezil Involve miR-206-3p in the Hippocampus and Cortex
Cheng-Niu Wang et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2017)
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma
M. H. van der Ree et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Bruno Dubois et al.
ALZHEIMERS & DEMENTIA (2016)
Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisenseoligonucleotides
Anthony J. Hinrich et al.
EMBO MOLECULAR MEDICINE (2016)
Peripheral Administration of GSK-3β Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease
Susan A. Farr et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer's disease
Yueqi Zhang et al.
NEUROTOXICOLOGY (2016)
Splice-switching antisense oligonucleotides as therapeutic drugs
Mallory A. Havens et al.
NUCLEIC ACIDS RESEARCH (2016)
MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice
Yueqi Zhang et al.
SCIENTIFIC REPORTS (2016)
Therapeutic Effects of Transplantation of As-MiR-937-Expressing Mesenchymal Stem Cells in Murine Model of Alzheimer's Disease
Zhen Liu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo
Pascal Y. Smith et al.
HUMAN MOLECULAR GENETICS (2015)
Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau
Ismael Santa-Maria et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain
Jaekwang Kim et al.
JOURNAL OF NEUROSCIENCE (2015)
Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression
Asad Jan et al.
NEUROSCIENCE LETTERS (2015)
Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease
Sepideh Parsi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease
Susan A. Farr et al.
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Central and Peripheral Administration of Antisense Oligonucleotide Targeting Amyloid-β Protein Precursor Improves Learning and Memory and Reduces Neuroinflammatory Cytokines in Tg2576 (AβPPswe) Mice
Susan A. Farr et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Luca F. R. Gebert et al.
NUCLEIC ACIDS RESEARCH (2014)
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Frank Rigo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Mercaptoacetamide-based class II HDAC inhibitor lowers A beta levels and improves learning and memory in a mouse model of Alzheimer's disease
You Me Sung et al.
EXPERIMENTAL NEUROLOGY (2013)
Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: A proteomics study
Ada Fiorini et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Transition of a microRNA from Repressing to Activating Translation Depending on the Extent of Base Pairing with the Target
Ashesh A. Saraiya et al.
PLOS ONE (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model
Soon-Tae Lee et al.
ANNALS OF NEUROLOGY (2012)
95. Antisense directed against the amyloid precursor protein reduces cytokine expression in the brain and improves learning and memory in the Tg2576 mouse model of Alzheimer’s disease
M.A. Erickson et al.
BRAIN BEHAVIOR AND IMMUNITY (2012)
MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1
Hong-Can Zhu et al.
BRAIN RESEARCH BULLETIN (2012)
Peripheral Administration of Antisense Oligonucleotides Targeting the Amyloid-β Protein Precursor Reverses AβPP and LRP-1 Overexpression in the Aged SAMP8 Mouse Brain
Michelle A. Erickson et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice
Wei Liu et al.
NEUROBIOLOGY OF AGING (2012)
The potential role of microRNA-146 in Alzheimer's disease: Biomarker or therapeutic target?
Li-Ling Wang et al.
MEDICAL HYPOTHESES (2012)
The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease
Marong Fang et al.
TOXICOLOGY LETTERS (2012)
MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed
Justin M. Long et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Highly Efficient miRNA-Mediated Reprogramming of Mouse and Human Somatic Cells to Pluripotency
Frederick Anokye-Danso et al.
CELL STEM CELL (2011)
miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation
Xiaoying Wang et al.
BRAIN RESEARCH BULLETIN (2009)
Most mammalian mRNAs are conserved targets of microRNAs
Robin C. Friedman et al.
GENOME RESEARCH (2009)
New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites
Inhan Lee et al.
GENOME RESEARCH (2009)
MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation
Ulf Andersson Orom et al.
MOLECULAR CELL (2008)
Antisense inhibition at the β-secretase-site of β-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in TG2576
Neelima B. Chauhan et al.
NEUROSCIENCE (2007)
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice
AL Fu et al.
BRAIN RESEARCH (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
